Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $1.45 USD
Change Today -0.0187 / -1.27%
Volume 31.7K
CASI On Other Exchanges
As of 8:10 PM 05/5/15 All times are local (Market data is delayed by at least 15 minutes).

casi pharmaceuticals inc (CASI) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/8/14 - $2.09
52 Week Low
12/18/14 - $1.07
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

casi pharmaceuticals inc (CASI) Related Businessweek News

No Related Businessweek News Found

casi pharmaceuticals inc (CASI) Details

CASI Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops therapeutics to treat cancer and other diseases primarily in the United States and China. The company’s lead drug candidate includes ENMD-2076, an Aurora A and angiogenic kinase inhibitor for the treatment of cancer, which has completed Phase I studies in patients with advanced solid tumors, multiple myeloma, and leukemia, as well as it is completing data for a multi-center Phase II study in patients with platinum resistant ovarian cancer. Its other product candidates in development include 2-methoxyestrdiol, an orally active compound for autoimmune diseases; and MKC-1, an orally-active cell cycle inhibitor that has completed Phase II clinical trials for cancer treatment. The company name was formerly known as EntreMed, Inc. and changed its name to CASI Pharmaceuticals, Inc. in June 2014. CASI Pharmaceuticals, Inc. was founded in 1991 and is headquartered in Rockville, Maryland.

20 Employees
Last Reported Date: 03/27/15
Founded in 1991

casi pharmaceuticals inc (CASI) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $300.0K
Principal Accounting Officer and Vice-Preside...
Total Annual Compensation: $175.1K
Chief Operating Officer, General Counsel and ...
Total Annual Compensation: $300.0K
Compensation as of Fiscal Year 2014.

casi pharmaceuticals inc (CASI) Key Developments

CASI Pharmaceuticals, Inc. Receives Approval from CFDA for Phase 2 Clinical Trial in China with ENMD-2076 for Ovarian Clear Cell Carcinoma

CASI Pharmaceuticals, Inc. announced that the China Food and Drug Administration (CFDA) has approved the company's application to conduct a Phase 2 global clinical trial in ovarian clear cell carcinoma (OCCC) patients for its proprietary drug candidate ENMD-2076. The approval will allow CASI to expand its ongoing Phase 2 OCCC trial currently underway in multiple centers in North America with Princess Margaret Cancer Centre in Toronto, Canada as the lead institution. This will be the company's third approval of a global Phase 2 clinical trial in China, the first being for advanced triple-negative breast cancer in which the first patient was enrolled last week at the Cancer Hospital of Chinese Academyof Medical Science in Beijing and the second being for advanced soft tissue sarcoma. Data from this China trial will be evaluated in conjunction with data being collected in the Canadian/US trials in an effort to further advance the development of ENMD-2076.

CASI Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Year Ended December 31, 2014

CASI Pharmaceuticals, Inc. reported earnings results for the fourth quarter and year ended December 31, 2014. For the quarter, total revenue was $23,727. Net loss was $1,596,677 or $0.05 per basic and diluted common share against $1,308,468 or $0.05 per basic and diluted common share a year ago. The increase in net loss can be attributed to higher costs associated with expanding China operations as well as increased investments in business development and investor relations activities. For the year, total revenue was $23,727. Net loss was $26,202,308 or $0.92 per basic and diluted common share against $5,738,361 or $0.22 per basic and diluted common share a year ago.

Casi Pharmaceuticals Announces Initiation of Phase 2 Trial with ENMD-2076 in Triple-Negative Breast Cancer in China

CASI Pharmaceuticals, Inc. announced that it has initiated a Phase 2 trial of its target therapy drug candidate ENMD-2076 in triple-negative breast cancer (TNBC) at the Cancer Hospital of Chinese Academyof Medical Sciences in Beijing, China. This Phase 2 trial is an expansion of the current U.S. Phase 2 trial that is underway at the University of Colorado Cancer Center and the Melvin and Bren Simon Cancer Center at Indiana University. The China trial will assess safety and efficacy of ENMD-2076 in the Chinese patient population with correlative bio-marker analysis.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CASI:US $1.45 USD -0.0187

CASI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Novartis AG SFr.93.80 CHF -0.95
Regeneron Pharmaceuticals Inc $465.50 USD -8.67
View Industry Companies

Industry Analysis


Industry Average

Valuation CASI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2,008.1x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 1,499.9x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CASI PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at